Rahnama 2010.

Methods	Study design: single‐centre RCT Number randomised: 32; intervention, not specified; control, not specified Study start: not reported; stop date: not reported Length of intervention: 15 weeks Length of follow‐up: to end of intervention Country: Iran
Participants	Age, years: 50 to 65 Stage: stage I‐IIIB Inclusion criteria: • 50 to 65 years old • Women who received surgery, chemotherapy, and radiotherapy and currently were taking hormone therapy • Stage I‐IIIB • No specific illness in the past 6 months • No experience of a menstrual cycle • No participation in exercise training or physical activity in the past 6 months • No change in body weight during this period (last 6 months) as great as 10% of their whole body weight Exclusion criteria: • None reported
Interventions	The number of participants assigned to the exercise intervention was not specified: Participants took part in supervised walking programme 2 times per week at 45% maximum heart rate during weeks 1 to 5, 55% maximum heart rate during weeks 6 to 10, and 65% maximum heart rate during weeks 11 to 15. The duration of walking progressed from 25 minutes during weeks 1 to 5 to 35 minutes during weeks 6 to 10. Resistance training (60 minutes per session) was performed on different days from walking and included 9 resistance training exercises performed on Cybex strength training equipment (Smith press squats, leg press, leg extension, seated leg curl, lat pull‐downs) and with free weights (bench press, overhead press, biceps curls, and triceps kickbacks). Adherence: not reported Number of participants assigned to control not specified: Control group participated in measurements only and were asked not to participate in any physical activity or exercise training. All participants were asked to avoid changes in dietary habits for weight loss purposes for the duration of the study.
Outcomes	Outcomes: Weight, BMI, waist and hip circumferences Blood pressure measured with a Japanese sphygmomanometer model ALPK2 in seated position Resting heart rate measured each morning with the heart rate monitor belt VO₂max assessed by modified Bruce protocol Insulin measured by electrochemiluminescent immunoassay; glucose measured with a hexokinase ultraviolet assay; insulin resistance calculated by the HOMA; LDL‐C and triglycerides measured enzymatically Numbers of participants assessed: Intervention: baseline, not specified; at 15 weeks, 14 Control: baseline, not specified; at 15 weeks, 15 Adverse events: not reported
Notes	Trial registration link: none available Trial authors contacted: no Intention‐to‐treat analysis: no Funding: none specified
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Generation of the random sequence was not described.
Allocation concealment (selection bias)	Unclear risk	Whether treatment assignment was concealed from study personnel and participants was not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Owing to the nature of the intervention, it was not possible to conceal allocation to the intervention from participants.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	“All the measurements were obtained twice and recorded by one staff that was blinded to subjects in pre‐ and post‐tests”.
Incomplete outcome data (attrition bias) All outcomes	High risk	Three participants withdrew during the study period; reasons for withdrawals were not reported. No intention‐to‐treat analysis was performed.
Selective reporting (reporting bias)	Low risk	No selective reporting of outcomes is apparent.
Other bias	Low risk	Trial appears to be free of other problems that could put it at high risk of bias.